A detailed history of Boothbay Fund Management, LLC transactions in Insmed Inc stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 264,700 shares of INSM stock, worth $17.5 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
264,700
Previous 101,900 159.76%
Holding current value
$17.5 Million
Previous $6.83 Million 183.04%
% of portfolio
0.54%
Previous 0.2%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $1.88 Million - $2.39 Million
30,301 Added 225.86%
43,717 $3.19 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $689,986 - $2.19 Million
-31,363 Reduced 70.04%
13,416 $898,000
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $1.15 Million - $1.34 Million
44,779 New
44,779 $1.21 Million
Q3 2023

Nov 14, 2023

SELL
$19.86 - $26.93 $1.32 Million - $1.78 Million
-66,250 Reduced 68.06%
31,089 $784,000
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $1.58 Million - $2.12 Million
97,339 New
97,339 $1.66 Million
Q2 2022

Aug 15, 2022

BUY
$17.07 - $25.71 $272,266 - $410,074
15,950 New
15,950 $315,000
Q4 2021

Feb 14, 2022

SELL
$25.89 - $33.45 $208,518 - $269,406
-8,054 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$22.46 - $29.47 $18,619 - $24,430
-829 Reduced 9.33%
8,054 $222,000
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $214,702 - $319,876
8,883 New
8,883 $253,000
Q2 2020

Aug 14, 2020

SELL
$14.11 - $29.42 $273,987 - $571,277
-19,418 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$13.63 - $33.98 $264,667 - $659,823
19,418 New
19,418 $311,000
Q1 2018

May 14, 2018

SELL
$21.69 - $32.99 $313,203 - $476,375
-14,440 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$26.43 - $31.78 $138,731 - $166,813
5,249 Added 57.11%
14,440 $450,000
Q3 2017

Nov 14, 2017

BUY
$11.61 - $31.21 $106,707 - $286,851
9,191
9,191 $287,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.